维普期刊资源整合服务平台（V6.5）

46篇 您的检索式：作者名="Reckamp KL"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin显示文摘	Reckamp KL Gardner BK Figlin RA	2008	J Thorac Oncol2008，3，2：	1
2	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non- Small-Cell Lung Cancer显示文摘	Brahmer J Reckamp KL Baas P	2015	N Engl J Med2015，373，2：	1
3	A phase 2 trial of dacomitinib ( PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor ) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib 显示文摘	Reckamp KL Giaccone G Camidge DR	2014	Cancer2014，120，8：	1
4	Nivolumab versus Do- cetaxel in Advanced Squamous - Cell Non - Small - Cell Lung Cancer显示文摘	Brahmer J Reckamp KL Baas P	2015	N Engl J Med2015，373，2：	1
5	Non-small cell lung cancer in the elderly : defining treatment options 显示文摘	Vora N Reckamp KL	2008	Semin Oncol2008，35，：	1
6	Chemokines as therapeutic targets in renal cell carcinoma显示文摘	Reckamp KL Stricter RM Figlin RA	2008	Expert Rev Anticancer Ther2008，8，6：	1
7	, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cane- er显示文摘	BrahmerJ Reckamp KL Baas P et ol	2015	N Engl J Med2015，373，：	1
8	Phase II trial of XLl84 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303)显示文摘	RECKAMP KL FRANKEL PF MACK PC	2014	J Clin Oneol2014，32，5：	1
9	A phaseⅠtrial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced nonsmall cell lung cancer显示文摘	Reckamp KL Krysan K Morrow JD Milne GL Newman RA Tucker C	2006	Clin Cancer Res2006，12，111：	1
10	A phase Ⅲ study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC) 显示文摘	Spigel DR Reckamp KL Rizvi NA	2015	J Clin Oncol2015，33，15：	1
11	Management of non-small-cell lung cancer in the older adult显示文摘	Vander Walde A Pal SK Reckamp KL	2011	Maturitas2011，68，4：	1
12	The potential and rational for cox-2 inhibitors in lung cancer显示文摘	Krysan K Reckamp KL Sharma S		0，，3：	1
13	CXCR4 expression on circulating' pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer 显示文摘	Reckamp KL Fighn RA Burdick MD	2009	BMC Cancer2009，9，：	1
14	Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer 显示文摘	Brahmer J Reckamp KL Baas P	2015	N Engl J Med2015，373，2：	1
15	Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer显示文摘	Brahmer J Reckamp KL Baas P	2015	N Engl J Med2015，373，2：	1
16	Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase- 9 and a decline in serum-soluble E-cadherin显示文摘	Reckamp KL Gardner BK Figlin RA	2008	J Thorac Oncol2008，3，2：	1
17	A phase 1 trial to determine the optimal biological dose of eelecoxib when combined with erlotinib in advanced non-small cell lung cancer 显示文摘	Reckamp KL Krysan K Morrow JD	2006	Clin Cancer Res2006，12，：	1
18	A phase 2 trial of dacomitinib (PF -D0299804 ), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib显示文摘	Reckamp KL Giaccone G Camidge DR	2014	Cancer2014，120，8：	1
19	Antiangiogenic agents as second ~ line therapy for advanced non-small cell lung cancer显示文摘	Reckamp KL	2012	Cancer Lett2012，321，2：	1
20	Nivolumab versus docetaxel in advanced squamous-cell non-small- cell lung cancer显示文摘	Brahmer J Reckamp KL Baas P	2015	N EngIJ Med2015，373，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示